Matt Gethers/Articles of General Interest/Biologically Encoded Safety Mechanisms

Biologically Encoded Safety Mechanisms

Mechanisms Currently in Use

1. Amado RG and Chen IS. Lentiviral vectors--the promise of gene therapy within reach?. Science. 1999 Jul 30;285(5428):674-6. DOI:10.1126/science.285.5428.674 |
2. Iwakuma T, Cui Y, and Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology. 1999 Aug 15;261(1):120-32. DOI:10.1006/viro.1999.9850 |
3. Kappes JC, Wu X, and Wakefield JK. Production of trans-lentiviral vector with predictable safety. Methods Mol Med. 2003;76:449-65. DOI:10.1385/1-59259-304-6:449 |
4. Miyoshi H, Blömer U, Takahashi M, Gage FH, and Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998 Oct;72(10):8150-7. DOI:10.1128/JVI.72.10.8150-8157.1998 |
5. Sikorski R and Peters R. Gene therapy. Treating with HIV. Science. 1998 Nov 20;282(5393):1438. DOI:10.1126/science.282.5393.1438a |
6. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, and Sanda MG. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst. 1999 Jan 20;91(2):169-75. DOI:10.1093/jnci/91.2.169 |
7. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, and Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998 Dec;72(12):9873-80. DOI:10.1128/JVI.72.12.9873-9880.1998 |

Potential Mechanisms

8. Hohsaka T, Ashizuka Y, Taira H, Murakami H, and Sisido M. Incorporation of nonnatural amino acids into proteins by using various four-base codons in an Escherichia coli in vitro translation system. Biochemistry. 2001 Sep 18;40(37):11060-4. DOI:10.1021/bi0108204 |
9. Wang L, Brock A, Herberich B, and Schultz PG. Expanding the genetic code of Escherichia coli. Science. 2001 Apr 20;292(5516):498-500. DOI:10.1126/science.1060077 |

Church Article

Church Article 2